Phase 2 clinical trial will evaluate the safety, translational biology, and exploratory clinical efficacy of VYD2311 in people with Long COVID or COVID vaccine injuryParticipants to include people ...

Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to ...

That price equates to an aggregate equity value of $2.2 billion, according to GSK, who added that the upfront investment net ...

Orphai Therapeutics Inc. ('Orphai”), a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for ...

RAPT Therapeutics, Inc. is being acquired by GSK plc for $2.2B as ozureprubart targets IgE disorders with 8–12 week dosing.

Sanofi's acquisition of Dynavax, valued at $2.2 billion, aims to enhance its vaccine portfolio, including a promising shingles vaccine candidate, Z-1018. Z-1018 has demonstrated comparable ...

The phase 2a trial showed GR-0621 met primary and secondary endpoints, demonstrating safety and efficacy over 12 weeks. Phase 2a data show oral GRI-0621 was safe and improved immune and fibrosis ...

Sofetabart mipitecan is an antibody-drug conjugate consisting of an Fc-silent, folate receptor alpha specific monoclonal antibody attached to an exatecan payload.

Corvus Pharma reports encouraging data for its eczema drug soquelitinib, showing strong skin improvement and no serious ...

Intismeran autogene with pembrolizumab shows a 49% reduction in recurrence or death risk in high-risk resected melanoma ...

CO2 reduction to storable fuels or valuable chemical products provides a carbon-neutral cycle that can mitigate the rapid ...

Boundless persevered with the other drug, a CHK1 inhibitor BBI-355, as a monotherapy for oncogene-amplified solid tumors. But the clinical data showed signs of hematological toxicity that would have ...